Human pluripotent stem cells (hPSCs) constitute a promising resource for use in cell-based therapies and a valuable in vitro model for studying early human development and disease. Despite significant advancements in the derivation of specific fates from hPSCs, the generation of skeletal muscle remains challenging and is mostly dependent on transgene expression. Here, we describe a method based on the use of a small-molecule GSK3b inhibitor to derive skeletal muscle from several hPSC lines. We show that early GSK3b inhibition is sufficient to create the conditions necessary for highly effective derivation of muscle cells. Moreover, we developed a strategy for stringent fluorescence-activated cell sorting-based purification of emerging PAX3+/PAX7+ muscle precursors that are able to differentiate in postsort cultures into mature myocytes. This transgene-free, efficient protocol provides an essential tool for producing myogenic cells for in vivo preclinical studies, in vitro screenings, and disease modeling.
INTRODUCTION
Pluripotent stem cells (PSCs) such as embryonic stem cells (ESCs) and induced PSCs (iPSCs) provide an extraordinary research tool. In vitro, these cells display extensive proliferation and the ability to differentiate into derivatives of all three germ layers. Such characteristics give these cells a remarkable potential for use in cell-based therapies as well as an in vitro model for early human development. PSC differentiation protocols are currently available for a vast number of cell types (Trounson, 2006) ; however, little progress has been made regarding differentiation of PSCs into derivatives of paraxial mesoderm, such as skeletal muscle. The difficulty lies in our limited knowledge about specific inductive signals and their timing of expression required for myogenic induction of paraxial mesoderm. The appropriate combination of markers for efficient isolation of skeletal muscle precursors also remains to be determined. As such, only a few studies have reported the derivation of skeletal muscle cells from human PSCs (hPSCs), and they mostly utilized an approach that relies on forced transgene expression to induce myogenesis (Darabi et al., 2012; Goudenege et al., 2012; Ryan et al., 2012) . Although a derivation protocol based on the use of genetically modified PSCs can be successful, it does not reflect normal development, does not provide clear information about the identity of the cells generated, and, most importantly, is not suitable for therapeutic purposes or in vitro disease modeling.
We previously reported the generation of specialized, multipotent mesenchymal precursors from hESCs and their directed differentiation into skeletal muscle cells (Barberi et al., 2007) . Although that report showed the derivation of skeletal muscle cells from hESCs, the percentage of mesenchymal cells with myogenic potential showed substantial variability. Here, we sought to develop a tightly controlled method to direct hPSCS through defined developmental events leading to the derivation of committed skeletal muscle precursors.
Following a simple two-step differentiation protocol, we first induced paraxial mesoderm by treating hPSCs with a WNT agonist, the small-molecule glycogen synthase kinase-3 inhibitor (CHIR 99021) (Cohen and Goedert, 2004; Tan et al., 2013) . In addition to paraxial mesoderm induction, canonical WNT activation acted as a dorsalizing agent, promoting the generation of dorsal neuroepithelial and neural crest cells (Chizhikov and Millen, 2004; Ikeya et al., 1997; Menendez et al., 2011) . These cells provide the essential cues for patterning of the paraxial mesoderm and activation of the myogenic program within our cultures (Rios et al., 2011; Tajbakhsh and Buckingham, 2000) . Subsequent expansion of the myogenic compartment was achieved through the addition of fibroblast growth factor 2 (FGF2) (Chakkalakal et al., 2012; Lagha et al., 2008) .
To isolate skeletal muscle cells generated from our system, we set up a stringent cell-sorting strategy using the muscle-specific nicotinic acetylcholine receptor (AChR) (Karlin, 2002) , the chemokine receptor CXCR4 (Buckingham, 2006; Vasyutina et al., 2005) , and the hepatocyte growth factor receptor C-MET/HGF (Bladt et al., 1995; Dietrich et al., 1999) . Due to their functional roles in hypaxial migratory skeletal muscle, CXCR4 and C-MET allow the isolation of PAX3+ PAX7+ skeletal muscle precursors at high purity (Relaix et al., 2005) . Our protocol has been successfully tested on several PSC lines and provides an invaluable standardized tool for the directed derivation of transgene-free myogenic cells for in vivo preclinical studies and for in vitro functional assays and drug screening.
RESULTS

Derivation of Skeletal Muscle Cells from hPSCs
We initiated differentiation of hPSCs at medium to large colony size (diameter 600 mm) and low colony density in serum-free medium consisting of Dulbecco's modified Eagle's medium F-12 (DMEM-F12) supplemented with insulin, transferrin, and selenium (ITS). Paraxial mesoderm specification of hPSCs was achieved through activation of WNT/beta-catenin signaling mediated by the smallmolecule GSK-3b inhibitor CHIR 99021 (Cohen and Goedert, 2004; Tan et al., 2013) . GSK-3b is known to target a number of substrates for phosphorylation, one of which is beta-catenin, an integral transducer within the canonical WNT signaling pathway. Therefore, inhibition of GSK-3b activity prevents the targeted phosphorylation of beta-catenin, rendering it resistant to degradation and thus leading to activation of T cell factor (TCF)-mediated transcription of downstream target genes (Wu and Pan, 2010) . In addition to paraxial mesoderm, WNT signaling is a potent inducer of dorsal cell fates such as roof plate, neural crest, and nonneural ectoderm, marked by LMX1A, SOX10, and AP2a, respectively (Gammill and Bronner-Fraser, 2003; Millonig et al., 2000;  Figure S1 available online).
hPSCs were first exposed to 3 mM CHIR for 4 days and then the small molecule was replaced with 20 ng/ml of FGF2 for an additional 2 weeks ( Figure 1A ). To optimize the differentiation of hPSCs toward a myogenic phenotype, we tested different CHIR concentrations and found high toxicity at >3 mM and inefficient induction at doses of <3 mM (data not shown). The FGF signaling pathway has been identified to regulate several developmental processes of muscle formation. During somitogenesis, segmentation determination is mediated by an FGF signaling gradient within the presomitic mesoderm (Aulehla and Pourquié, 2010) . Significantly, FGF molecules such as FGF2 have been described as potent inducers of mitogenic activity in both embryonic skeletal muscle precursors and adult satellite cells (Chakkalakal et al., 2012 ; Lagha et al., Stem Cell Reports GSK-3b Inhibition Promotes Skeletal Muscle from hPSC 2008). As such, our primary reason for adding FGF2 was to drive expansion of the muscle progenitor compartment within our culture system. Following withdrawal of FGF2 and a further 17 days of culture in ITS medium alone, areas with skeletal muscle cells were scored in treated culture dishes prior to FACS analysis, and identified by immunocytochemistry as PAX3+ and PAX7+ precursors ( Figure 1B ; Relaix et al., 2005) and bipolar skeletal myocytes positive for myogenin and sarcomeric myosin (MF20) ( Figure 1C ). Quantitative analysis revealed the percentage of total PAX3+/PAX7+ and MF20+ muscle cells within the cell culture to be >18% and >8%, respectively, demonstrating the robustness of our treatment strategy.
To further profile the efficacy of our treatment, we analyzed the expression of key regulatory genes associated with the acquisition of a myogenic cell fate by quantitative PCR (qPCR). Data were acquired during a fixed 3-day interval starting at day 0 and ending at day 30 of in vitro differentiation in CHIR+FGF2 compared with untreated hPSCs (Figure 2 ). Expression profiling of differentiating hPSCs over the course of treatment showed the guided progression of hPSCs through key myogenic milestones. Inhibition of GSK3b resulted in a marked increase in the expression of paraxial/presomitic mesoderm genes such as TBX6, Mesogenin (MSGN1) (Wittler et al., 2007) , and MESP1 (Chan et al., 2013) , with an early peak at day 3 of differentiation. Subsequent PARAXIS (Burgess et al., 1996) activation starting at day 9 of differentiation indicated progression toward somitic mesoderm. Significantly, expression of the muscle specification genes SIX1 and SIX4 (Grifone et al., 2005) , PAX3, PAX7, and the migratory muscle progenitor marker LBX1 (Gross et al., 2000; Schäfer and Braun, 1999) exhibited marked activation at day 21 of differentiation under the treatment conditions. Expression of the myogenic regulatory factors MYF5 and MYOD indicated muscle commitment and progression of the myogenic differentiation program (Rudnicki et al., 1993) . In contrast, an insignificant activation of myogenicspecifier genes occurred during differentiation of untreated hPSCs.
Interestingly, PARAXIS exhibited a second peak of expression beginning at day 21, correlating with the activation of SIX1, SIX4, PAX3, and PAX7. Although it is known to regulate somite epithelization, Paraxis has also been shown to be expressed in migratory hypaxial muscle progenitors (Delfini and Duprez, 2000) . Therefore, secondary activation of PARAXIS expression, in conjunction with expression of LBX1, suggests a bias toward hypaxial myogenesis within our system.
FACS Isolation of Hypaxial Skeletal Muscle Precursors
The expression of the migratory skeletal muscle progenitor marker LBX1 observed in CHIR-treated differentiating hPSCs led us to purify this putative migratory muscle compartment by using CXCR4 and C-MET surface markers, which together are reported to define migratory muscle precursors. Within the hypaxial domain of the embryonic dermomyotome, C-MET expression is critical for the delamination of PAX3+ LBX1+ migratory muscle precursors (Bladt et al., 1995; Dietrich et al., 1999) , whereas the subsequent survival and distribution of precursors at the site of migration is CXCR4 dependent (Buckingham, 2006; Vasyutina et al., 2005) . However, CXCR4 and C-MET may also be expressed in cells of different origins, such as neural and neural crest cells, respectively (Kos et al., 1999; Zhu and Murakami, 2012) . Therefore, to exclude these cell types, we used CD57/ HNK-1 as a negative selection marker (Morita et al., 2008) . Although CXCR4 can be used to define and isolate definitive endoderm from hPSCs (Teo et al., 2012) , the CHIR treatment used in our protocol was not permissive for the generation of endoderm cells, as confirmed by the lack of specific endodermal markers in our cultures (data not shown). Because of the observed activation of myogenic specification genes beginning at day 21 of hPSC differentiation (Figure 2 ), we isolated skeletal muscle precursors by FACS at three time points (days 25, 30, and 35). The following cell populations were isolated: HNKÀ/AChRÀ/CXCR4À/C-METÀ (all negative), HNKÀ/ AChRÀ/CXCR4+/C-METÀ (CXCR4+/C-METÀ), HNKÀ/ AChRÀ/CXCR4+/C-MET+ (CXCR4+/C-MET+), and HNKÀ/AChRÀ/CXCR4À/C-MET+ (CXCR4À/C-MET+). A detailed gating strategy for the FACS protocol is shown in Figure 3 .
Postsorting analysis revealed the presence of myogenic cells only in the populations in which CXCR4 and/or C-MET were present (CXCR4+/C-METÀ, CXCR4+/C-MET+, and CXCR4À/C-MET+; Figure 4) . To quantify the level of purity in these populations, we performed an immediate postsort immunocytochemical analysis on cytospin preparations. The cytocentrifugation technique spins a cell suspension onto a defined area of a glass slide, creating a monolayer of flattened cells and thus allowing Stem Cell Reports GSK-3b Inhibition Promotes Skeletal Muscle from hPSC prominent nuclear presentation. Based on nuclear staining, only CXCR4À/C-MET+ and CXCR4+/C-MET+ cell populations allowed the isolation of highly pure skeletal muscle precursors. At day 35, the percentage of total cells immunoreactive for the muscle stem cell marker PAX3 was 97% ± 0.5% in CXCR4À/C-MET+ and 98% ± 0.2% in CXCR4+/C-MET+. The percentage of PAX7 was 84% ± 1.7% in CXCR4À/C-MET+ and 96% ± 2.8% in CXCR4+/ C-MET+ ( Figure 4A ). Immunocytochemical analysis of precursor populations sorted at earlier time points revealed developmental progression of the myogenic program. CXCR4À/C-MET+ and CXCR4+/C-MET+ cells sorted at day 23 were characterized by expression of early myogenic specifier genes SIX4 and PAX3 prior to PAX7 expression. Subsequent acquisition of PAX7 expression, starting at day 25, marked lineage progression ( Figure S2 ). By day Figure 4A ). However, an overall lower expression of PAX7 was observed in CXCR4À/C-MET+ cells compared with CXCR4+/C-MET+ cells. Given the earlier activation of Pax3 (Horst et al., 2006) and the expression of Cxcr4 in late-stage migratory precursors (Vasyutina et al., 2005) during muscle development, we speculate that CXCR4À/C-MET+ cells could represent a more primitive progenitor population.
Postsorting cultures of CXCR4À/C-MET+ and CXCR4+/ C-MET+ cells isolated at day 35 of hPSC differentiation confirmed the validity of the sorting strategy, with all plated cells from both populations undergoing progressive terminal muscle differentiation as shown by expression of MYF5, MYOG, and MF20 ( Figure 4B ). After 3 days of culture, few cells retained expression of PAX7, whereas all cells expressed MYF5, indicating muscle commitment. By day 9 the majority of cells were in an advanced stage of muscle differentiation.
Gene-expression analysis by RT-PCR confirmed the immunocytochemical data, demonstrating the presence of PAX3 and PAX7 mRNA transcripts together with LBX1 in both CXCR4À/C-MET+ and CXCR4+/C-MET+ sorted populations, and, importantly, their absence in all negative cell populations ( Figure 4C ).
Although it was enriched in muscle precursors, the CXCR4+/C-METÀ cell population showed heterogeneity, with gene-expression analysis revealing the presence of muscle together with SOX1+ neural cells ( Figure 4C ), and thus would not be useful for in vitro or in vivo studies.
Single-Step FACS Isolation of Mature Skeletal Myocytes
In addition to their potential use in clinical applications, enriched populations of hPSC-derived skeletal muscle cells also provide a platform for basic research investigations. Purification of hPSC-derived mature myocytes offers an unlimited source of cells for large-scale screening of novel therapeutic compounds and toxicity studies. Here, we developed a simple single-antigen strategy for the direct isolation and purification of mature skeletal myocytes.
In our two-step culture system, bipolar skeletal myocytes appeared at approximately 4 weeks of hPSC differentiation. Immunocytochemical analysis revealed strong expression of the muscle-specific nicotinic AChR on these cells (Figure 5A ). These receptors are among the first membrane 
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proteins to be expressed during skeletal muscle development. However, their presence is required only later during synaptogenesis, when they mediate synaptic transmission at the neuromuscular junction (Brehm and Henderson, 1988) . At days 30 and 35 of hPSC differentiation, an easily distinguishable AChR+ population (up to 8% of total cells) was identified and isolated by FACS ( Figure 5B ). Analysis of both AChR+ and AChRÀ fractions showed that expression of the mature muscle marker myosin heavy chain 2a (MYHC2) was restricted only to AChR+ cells ( Figure 5C ).
Following isolation, the AChR+ cells were plated onto fibronectin/laminin-coated plates in the presence of ITS medium. At 24 hr after plating, as expected, all AChR+ cells were immunoreactive for the mature muscle markers myogenin and MF20 ( Figure 5D ). Prolonged cell culture (>20 days) of AChR+ cells led to the progressive fusion of myocytes into multinucleated myotubes ( Figure 5E ).
GSK-3 Inhibition Is Required for Efficient Muscle Derivation
We next determined the efficacy of our two-step protocol by comparing four different sorted populations (AChR+, CXCR4+/C-MET+, CXCR4À/C-MET+, and CXCR4+/C-METÀ) derived under different culture conditions (CHIR+ FGF2, CHIR only, FGF2 only, and untreated). Muscle precursors were already present at day 25 of hPSC differentiation, as indicated by the presence of both CXCR4+/ C-MET+ ( Figure 6A -II) and CXCR4À/C-MET+ ( Figure 6A -III) cell populations. As expected, the overall percentage of each myogenic population increased over time, and thus at day 35, under CHIR+FGF2 treatment, we collectively obtained up to 20% of muscle cells from the AChR+, CXCR4+/C-MET+, and CXCR4À/C-MET+ cell populations ( Figures 6A-I , 6A-II, and 6A-III). Significantly, a large component of these cells consisted of PAX3+ and PAX7+ precursors (CXCR4+/C-MET+; CXCR4-/C-MET+), comprising more than 12% of total cells ( Figures 6A-II and 6A-III). A similar robust percentage of muscle cells was observed across all four cell lines (three hESCs and one hiPSC), demonstrating the efficiency of our two-step protocol ( Figure S3 ).
CHIR+FGF2 treatment resulted in the efficient derivation of muscle precursors; however, exposure of hPSCs to CHIR only was sufficient for myogenic induction. A reduction in the percentage of CXCR4+/C-MET+ and AChR+ populations compared with CHIR+FGF2 cultures indicated an active role for FGF2 in the expansion of the myogenic compartment ( Figures 6A-I , 6A-II, and 6B, top and middle). In stark contrast, the absence of CHIR treatment resulted in almost complete loss of both of these cell fractions ( Figures  6A-I, 6A -II, and 6B, top and middle). Interestingly, the overall percentage of CXCR4+/C-METÀ and CXCR4À/C-MET+ cells did not change significantly among the four different treatment conditions (Figures 6A-III, 6A-IV, and 6B, middle and bottom). However, a comparative analysis of cell composition among these cell fractions isolated from CHIR+FGF2-or FGF2-only-treated cultures revealed a fundamental shift from a myogenic to a nonmyogenic cell fate in the absence of CHIR treatment (Figure 7) . These data illustrate a requirement of CHIR-mediated GSK3b inhibition for the robust induction of muscle cells from hPSCs. The addition of FGF2 is then necessary to achieve optimal expansion of skeletal muscle precursors.
DISCUSSION
The successful use of hPSC-derived progeny for in vitro screening (e.g., for disease modeling, drug development, and toxicity studies) or regenerative medicine requires tight control of the cell differentiation process and isolation of pure, specialized cell types. At present, the controlled derivation and efficient isolation of hPSCderived myogenic precursors equivalent to in vivo PAX3+/PAX7+ satellite cells has not been accomplished. Attempts to derive such cells are hindered by our lack of knowledge about the essential factors required in vitro to recapitulate the in vivo patterning of myogenic somitic mesoderm and the timing of their distribution. This may explain the limited success to date and the large number of published protocols that rely on an artificial system of derivation utilizing forced transgene expression (Darabi et al., 2012; Goudenege et al., 2012) . Although Ryan et al. (2012) recently provided evidence of muscle differentiation from hESCs without genetic modification, their approach was hindered by the use of serum in the medium, low myogenic induction, and fundamentally the lack of any purification strategy.
Here, we present a simple, two-step differentiation method that recapitulates the early events of embryogenesis to efficiently derive PAX3+/PAX7+ skeletal muscle precursors from hPSCs. We demonstrate the feasibility of deriving robust numbers of skeletal muscle cells without the aid of transgene-driven differentiation.
Central to this method is the activation of canonical WNT signaling by the GSK3b inhibitor CHIR. Expression profiling of hPSCs over the course of guided differentiation showed progression through defined developmental milestones leading to myogenesis. This transition was initiated by a strong induction of TBX6, MESP1, and MSGN1 in CHIR-treated hPSCs, followed by high levels of PARAXIS expression, indicating progression into somitic mesoderm. In addition to the induction of paraxial mesoderm, activation of WNT signaling by CHIR was responsible for generating dorsal tissues, such as dorsal neural tube cells marked by LMX1A expression, along with SOX10+ neural crest cells and AP2a+ nonneural ectoderm ( Figure S1 ). It has been established that myogenic patterning of the dermomyotome requires WNT signaling from the dorsal neural tube and overlying ectoderm (Tajbakhsh and Buckingham, 2000) , together with transient, neural-crest-mediated notch activation of myogenic precursors (Rios et al., 2011) . Early GSK3b inhibition during hPSC differentiation allowed us to reproduce the conditions necessary for the specification of skeletal muscle cells, closely replicating the events that occur during normal development in vivo. We speculate that the generation of dorsal tissues played an essential role in delivering the appropriate signals required for the patterning of the presomitic mesoderm within our culture system. Conversely, prolonged exposure to CHIR for up to 10 days was shown to have a negative effect on muscle derivation, and no muscle cells were identified in the treated dishes (data not shown). Although we show that CHIR alone is sufficient for myogenic induction, prolonged FGF2 exposure proved to play a proliferative role 
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by significantly increasing the number of myogenic precursors.
We validated the robustness of our protocol by obtaining similar results with four hPSC lines, confirming that small-molecule-mediated GSK3b inhibition is a simple but highly efficient approach for directing the differentiation of hPSCs into skeletal muscle precursors.
Progress in considering hPSC-derived muscle as a valid source of cells for basic and translational research applications has been hindered by the lack of an efficient method to isolate muscle precursors. To overcome this limitation, we developed a FACS strategy to purify muscle precursors generated in our differentiation system. Since we detected LBX1 transcripts during directed myogenic commitment of hPSCs, we considered the use of two markers that are known to be highly expressed in hypaxial migratory muscle precursors during development: C-MET and CXCR4. FACS selection of two populations, CXCR4À/C-MET+ and CXCR4+/C-MET+, allowed the isolation of PAX3+/PAX7+ precursors at high purity. Notably, the negative cell population (HNKÀ/AChRÀ/ CXCR4À/C-METÀ) was devoid of any muscle markers, indicating not only that our sorting strategy is sufficient to isolate all skeletal muscle cells generated in our culture system but also that all PAX3+/PAX7+ precursors are of hypaxial origin. The specificity of this strategy is also confirmed by the complete absence of CXCR4+/C-MET+ cells and by a nonmuscle identity of CXCR4-/C-MET+ cells in the absence of early GSK3b inhibition during hPSC differentiation.
Transplantation of highly purified skeletal muscle precursors has been considered a possible option for the treatment of degenerative muscle disorders, such as muscular dystrophy. Our findings will accelerate the evaluation of the therapeutic potential of hPSC-derived muscle cells in preclinical models. Moreover, future applications of our method to patient-specific iPSC lines will aid in the study of muscle development during disease.
In addition to the isolation of skeletal muscle precursors, we described a simple strategy for the direct isolation of mature skeletal myocytes through the positive selection of AChR+ cells. This highly efficient derivation and direct isolation of mature embryonic stage skeletal myocytes provides a platform for developmental modeling and candidate drug screening.
In conclusion, we have developed a small-moleculebased approach and identified GSK3b inhibition as a requirement for the efficient, nongenetic derivation of skeletal muscle cells from hPSCs. Our cell-sorting strategy based on the use of functional markers allows the purification of hPSC-derived PAX3+/PAX7+ skeletal muscle precursors. This work describes the derivation and isolation of early muscle precursors with a defined phenotype.
EXPERIMENTAL PROCEDURES
Culture of Undifferentiated hPSCs
hPSC lines (WA-09 [H9], Mel1, HES3, and PDL-iPS), passages p40-65, were maintained on hESC-qualified Matrix (BDMatrigel; BD Biosciences) in the presence of mTESR1 medium (Stem Cell Technologies) as previously described (Ludwig and Thomson, 2007) . The experiments performed with hESCs in this study were approved by the Monash University Human Research Ethics Committee (CF09/2725).
Directed Differentiation of hPSCs into Skeletal Muscle Cells
Experiments were performed with all four hPSC lines. When the colony size reached >600 mm in diameter and the colony density on the plate was approximately 30%-40%, we induced differentiation of hPSC by switching the culture medium from mTESR1 to a chemically defined, serum-free medium, DMEM-F12, supplemented with ITS (all from Sigma-Aldrich). Starting at day 0 of differentiation, cells were cultured in the presence of 3 mM CHIR 99021 (Miltenyi Biotech) for 4 days. The culture medium was then replaced by ITS containing 20 ng/ml of FGF2 (Miltenyi Biotech) for a further 14 days. For each experimental control condition, hPSC differentiation was induced by (1) CHIR only (ITS medium containing 3 mM CHIR from days 0 to 4, followed by ITS medium only until the day of analysis) or (2) FGF2 only (ITS medium only between days 0 and 4, followed by ITS medium containing 20 ng/ml FGF2 for 14 days). The medium was replaced daily until the day of analysis.
FACS
Cells were dissociated with 0.05% trypsin or TrypLE Select (Invitrogen) to a single-cell suspension and incubated with the appropriate fluorochrome-labeled antibodies (Table S2 ) at a concentration of 10 7 cells/ml for 30 min on ice. Indirect labeling of HNK and AChR antibodies was done using goat anti-mouse Alexa Fluor 488 and goat anti-mouse PE (both from Molecular Probes/ Invitrogen) as secondary antibodies. Labeled cells were sorted through a BD Influx (five lasers) flow sorter (BD Biosciences) according to the excitation requirements of the fluorochromes. Sorted populations were analyzed using FlowJo software (Tree Star).
Immunocytochemistry
For cytospin preparations of FACS-sorted populations, cells were spun onto glass slides using Cytospin 4 (Shandon; Thermofisher). Cells were then fixed with 100% cold methanol for 5 min and subsequently rehydrated in PBS for 15-20 min. The cultured cells were fixed with 4% paraformaldehyde for 10 min at room temperature and permeabilized with 0.3% Triton X-100 in PBS for 30 min. A complete list of the primary and fluorochrome-labeled secondary antibodies used in this study is provided in 
Gene-Expression Analysis
Total RNA was extracted using the RNeasy Mini kit (QIAGEN), and DNase I treatment (QIAGEN) was performed to avoid genomic DNA contamination. The Ambion RETROscript First Strand Synthesis Kit (Invitrogen) was used to reverse transcribe total RNA (500 ng each sample). PCR was performed using the Mastercyler proS (Eppendorf AG). We optimized the PCR conditions and determined the linear amplification range for each primer by varying the annealing temperature and cycle number. Primer sequences, cycle numbers, and annealing temperatures are provided in Table S1 . All RT-PCR data shown are representative of one individual experiment. Three experiments per cell line were performed. Similar results were obtained in all cell lines. For qPCR, GAPDH was used as a reference gene and reactions were run using LightCycler480 SYBR Green I Master (Roche Applied Science) on a LightCycler 480 system (Roche Applied Science). Target gene expression was normalized to the reference gene (GAPDH), and subsequent quantification of gene expression was compared relative to day 0 undifferentiated hPSCs (Pfaffl, 2001 ).
Culture of FACS-Isolated Cell Populations
FACS-purified AChR+ myocytes and CXCR4À/C-MET+ and CXCR4+/C-MET+ precursors were plated onto tissue culture wells coated with 2 mg/ml fibronectin and 2 mg/ml laminin (both from Invitrogen) in ITS medium supplemented with 10 mM Rock Inhibitor Y-27632 (Sigma Aldrich). Myocytes were maintained in ITS medium in the presence of 50 ng/ml IGF1 (Peprotech) until they were analyzed. Progenitor cell populations were cultured in ITS medium until terminal muscle differentiation occurred.
Statistical Analysis
Data were analyzed by two-way ANOVA followed by Bonferroni's post test to calculate p values. Analyses were performed using statistical software (GraphPad Prism 5.04; GraphPad Software). Probability values < 0.05 were considered statistically significant. Error bars in each figure represent the SEM of three or more individual experiments. For qPCR data, p values were calculated for changes in expression of markers over time compared with day 0. For quantitative analysis of FACS sorting data, the percentage of myogenic cells relative to the total number of cells was obtained for each experimental culture treatment, and p values were calculated for differences between the means of each experimental condition.
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